Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion

Cancer Research

Volumn 67, Issue 4, 2007, Pages 1832-1841

  Lin, Ken Yu ^a   Lu, Dan ^a   Hung, Chien Fu ^a   Peng, Shiwen ^a   Huang, Lanqing ^a   Jie, Chunfa ^a   Murillo, Francisco ^a   Rowley, Jesse ^a   Tsai, Ya Chea ^a   He, Liangmei ^a   Kim, Dae Jin ^a   Jaffee, Elizabeth ^a   Pardoll, Drew ^a   Wu, T C ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4;

ANIMAL EXPERIMENT; ARTICLE; CANCER CELL; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MIGRATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; SITE DIRECTED MUTAGENESIS; TUMOR IMMUNITY; UPREGULATION;

ANIMALS; APOPTOSIS; BINDING SITES; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; DOWN-REGULATION; IMMUNOTHERAPY; INTEGRIN ALPHA4BETA1; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; ONCOGENE PROTEINS, VIRAL; REPRESSOR PROTEINS; UP-REGULATION; VACCINIA VIRUS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 33847700010     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3014     Document Type: Article

References (51)

1. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994;12:337-65.
2. Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2002;2:227-38.
3. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
4. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-60.
5. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002;3:999-1005.
6. Hicklin DJ, Marincola FM, Ferrone S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 1999;5:178-86.
7. Seliger B, Cabrera T, Garrido F, Ferrone S. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 2002;12:3-13.
8. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nat Med 2001;7:1118-22.
9. Yue FY, Dummer R, Geertsen R, et al. Interleukin-10 is a growth factor for human melanoma cells and downregulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer 1997;71:630-7.
10. Gabrilovich DI, Chen HL, Girgis KH, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096-103.
11. Sotomayor EM, Borrello I, Levitsky HI. Tolerance and cancer: a critical issue in tumor immunology. Crit Rev Oncog 1996;7:433-56.
12. Staveley-O'Carroll K, Sotomayor E, Montgomery J, et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci U S A 1998;95:1178-83.
13. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-61.
14. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
15. Singh S, Ross SR, Acena M, Rowley DA, Schreiber H. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J Exp Med 1992;175:139-46.
16. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800.
17. Munn DH, Mellor AL. IDO and tolerance to tumors. Trends Mol Med 2004;10:15-8.
18. Rubinstein N, Alvarez M, Zwirner NW, et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor immune privilege. Cancer Cell 2004;5:241-51.
19. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002;419:734-8.
20. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4249-64.
21. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003;19:185-93.
22. Kendziorski CM, Newton MA, Lan H, Gould MN. On parametric empirical Bayes methods for comparing multiple groups using replicated gene expression profiles. Stat Med 2003;22:3899-914.
23. Newton MA, Kendziorski CM, Richmond CS, Blattner FR, Tsui KW. On differential variability of expression ratios: improving statistical inference about gene expression changes from microarray data. J Comput Biol 2001;8:37-52.
24. Wang TL, Ling M, Shih IM, et al. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity. Gene Ther 2000;7:726-33.
25. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996;56:21-6.
26. Wu TC, Guarnieri FG, Staveley-O'Carroll KF, et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci U S A 1995;92:11671-5.
27. Cheng WF, Hung CF, Lin KY, et al. CD8+ T cells, NK cells and IFN-γ are important for control of tumor with downregulated MHC class I expression by DNA vaccination. Gene Ther 2003;10:1311-20.
28. Salomon DR, Mojcik CF, Chang AC, et al. Constitutive activation of integrin α4 β1 defines a unique stage of human thymocyte development. J Exp Med 1994;179:1573-84.
29. Mittelbrunn M, Molina A, Escribese MM, et al. VLA-4 integrin concentrates at the peripheral supramolecular activation complex of the immune synapse and drives T helper 1 responses. Proc Natl Acad Sci U S A 2004;101:11058-63.
30. Melder RJ, Koenig GC, Witwer BP, Safabakhsh N, Munn LL, Jain RK. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med 1996;2:992-7.
31. Fogler WE, Volker K, McCormick KL, Watanabe M, Ortaldo JR, Wiltrout RH. NK cell infiltration into lung, liver, and subcutaneous B16 melanoma is mediated by VCAM-1/VLA-4 interaction. J Immunol 1996;156:4707-14.
32. Pribila JT, Quale AC, Mueller KL, Shimizu Y. Integrals and T cell-mediated immunity. Annu Rev Immunol 2004;22:157-80.
33. 1. J Cell Biol 1994;125:1395-406.
34. Vonderheide RH, Tedder TF, Springer TA, Staunton DE. Residues within a conserved amino acid motif of domains 1 and 4 of VCAM-1 are required for binding to VLA-4. J Cell Biol 1994;125:215-22.
35. Jones EY, Harlos K, Bottomley MJ, et al. Crystal structure of an integrin-binding fragment of vascular cell adhesion molecule-1 at 1.8 Å resolution. Nature 1995;373:539-44.
36. Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004;6:1-6.
37. Rhodes DR, Yu J, Shanker K, et al. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A 2004;101:9309-14.
38. Simons JW, Jaffee EM, Weber CE, et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997;57:1537-46.
39. Miyake K, Medina K, Ishihara K, Kimoto M, Auerbach R, Kincade PW. A VCAM-like adhesion molecule on murine bone marrow stromal cells mediates binding of lymphocyte precursors in culture. J Cell Biol 1991;114:557-65.
40. Jacobsen K, Kravitz J, Kincade PW, Osmond DG. Adhesion receptors on bone marrow stromal cells: in vivo expression of vascular cell adhesion molecule-1 by reticular cells and sinusoidal endothelium in normal and γ-irradiated mice. Blood 1996;87:73-82.
41. Castro A, Bono MR, Simon V, Vargas L, Rosemblatt M. Spleen-derived stromal cells. Adhesion molecules expression and lymphocyte adhesion to reticular cells. Eur J Cell Biol 1997;74:321-8.
42. 1 (VLA4) integrin in T-cell development. Blood 1997;89:2461-71.
43. Koni PA, Joshi SK, Temann UA, Olson D, Burkly L, Flavell RA. Conditional vascular cell adhesion molecule 1 deletion in mice: impaired lymphocyte migration to bone marrow. J Exp Med 2001;193:741-54.
44. Vasselli JR, Shin JH, Iyengar SR, et al. Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc Natl Acad Sci U S A 2003;100:6958-63.
45. 2)-dependent T cell migration by augmenting the activation of focal adhesion kinase/proline-rich tyrosine kinase-2. J Immunol 2003;170:5912-8.
46. 4 cytoplasmic domain to regulate the reversible binding of paxillin. J Biol Chem 2003;278:34845-53.
47. Rose DM, Grabovsky V, Alon R, Ginsberg MH. The affinity of integrin α(4)β(1) governs lymphocyte migration. J Immunol 2001;167:2824-30.
48. 4 integrins and the immune response. Immunol Rev 2002;186:118-24.
49. 4 integrins modifies integrin-dependent biological responses. Nature 1999;402:676-81.
50. 4 cytoplasmic domain. Mol Biol Cell 1995;6:661-74.
51. Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 2004;4:118-32.